QRG Capital Management Inc. Has $3.93 Million Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

QRG Capital Management Inc. raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,772 shares of the company’s stock after acquiring an additional 360 shares during the quarter. QRG Capital Management Inc.’s holdings in Medpace were worth $3,929,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of MEDP. Private Advisor Group LLC raised its position in Medpace by 10.1% in the 1st quarter. Private Advisor Group LLC now owns 1,065 shares of the company’s stock worth $430,000 after purchasing an additional 98 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Medpace in the 1st quarter valued at $5,179,000. Janney Montgomery Scott LLC raised its position in shares of Medpace by 7.5% during the first quarter. Janney Montgomery Scott LLC now owns 7,630 shares of the company’s stock worth $3,084,000 after acquiring an additional 532 shares during the last quarter. Fidelis Capital Partners LLC acquired a new position in shares of Medpace during the first quarter valued at $31,000. Finally, Daiwa Securities Group Inc. boosted its holdings in Medpace by 391.6% in the first quarter. Daiwa Securities Group Inc. now owns 1,696 shares of the company’s stock valued at $686,000 after acquiring an additional 1,351 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MEDP has been the subject of several recent research reports. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. TD Cowen cut their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and lowered their target price for the stock from $415.00 to $345.00 in a report on Wednesday, September 25th. Robert W. Baird downgraded Medpace from an “outperform” rating to a “neutral” rating and cut their price target for the company from $413.00 to $349.00 in a research note on Wednesday, October 23rd. Finally, UBS Group cut Medpace from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $380.00.

Medpace Trading Up 9.1 %

NASDAQ:MEDP opened at $358.27 on Thursday. Medpace Holdings, Inc. has a 1 year low of $268.80 and a 1 year high of $459.77. The stock has a 50-day moving average price of $341.69 and a two-hundred day moving average price of $377.76. The stock has a market cap of $11.14 billion, a price-to-earnings ratio of 31.37, a PEG ratio of 1.76 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. The business had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Medpace’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.22 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.